A France-based company advancing a therapy for both solid tumours and haematologic malignancies has raised €96 million in a Series C financing round to establish clinical proof-of-concept for its lead antibody molecule. ImCheck Therapeutics SAS is located in Marseille and supported by a large group of investors including Andera Partners, Earlybird Venture and a philanthropy fund managed by the US Leukemia and Lymphoma Society.
